ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

J&J Opens Boston R&D Center

by Rick Mullin
July 8, 2013 | APPEARED IN VOLUME 91, ISSUE 27

Johnson & Johnson has started a pharmaceutical research innovation center in Boston. Aiming to take advantage of research environments in life sciences hubs, the company opened similar facilities earlier this year in London and Menlo Park, Calif., and intends to open a fourth in Shanghai. “The East Coast’s significance as a hotbed for life sciences innovation grounded in collaboration is indisputable,” says Paul Stoffels, J&J’s chief scientific officer. The firm joins major drug companies including Pfizer, Novartis, and AstraZeneca that have based drug research in the Boston area. Pfizer’s center in Cambridge, Mass., is part of a network, similar to J&J’s, that includes San Francisco, San Diego, and New York City. Similarly, Roche is establishing a translational medicine hub in New York City, where Eli Lilly & Co. also has labs. At an event marking the Boston center’s opening, J&J announced several research initiatives, including an alliance with the Icahn School of Medicine at Mount Sinai focused on inflammatory bowel disease and one with Rodin Therapeutics in the area of central nervous system disorders.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment